Skip to main content
Premium Trial:

Request an Annual Quote

TM Bioscience, Calgary Lab Services to Co-develop Dx for Pathogen

NEW YORK, Dec. 18 (Genome Web News) - Calgary Laboratory Services and Tm Bioscience plan to co-develop a gene-based diagnostic to help physicians identify and characterize nosocomial drug-resistant Staphylococcus aureus.

Currently, most labs employ cultures to diagnose the pathogen, methicillin-resistant S. aureus. And though molecular tests are used routinely at CLS and other large labs, "there are no standard commercial molecular assays available" to detect and characterize the pathogen.


The partnership marks the first time Tm Bioscience, based in Toronto, will focus on an infectious disease, the company said. CLS is located in Calgary and operates 18 patient-service centers and four hospital-based acute-care sites in the region, a CLS spokeswoman said.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.